This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex Pharmaceuticals’ (VRTX) new guidance for Casgevy “looks promising,” says the analyst, who adds that the setup for Crispr “appears even better than initially appreciated.”
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
Disclaimer & DisclosureReport an Issue
- Crispr Therapeutics price target raised to $45 from $40 at TD Cowen
- CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating
- Crispr Therapeutics price target lowered to $86 from $89 at BofA
- CRISPR Therapeutics: Buy-Rated, Multi-Franchise Gene-Editing Platform with Strengthening CASGEVY Launch and Catalyst-Rich 2026 Outlook
- Maintaining a Hold: Casgevy Outperformance Balanced by Pipeline Execution Risks and Limited Valuation Upside
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
